1. From the Division of Cardiovascular Medicine, Falk CVRC, Stanford University, Stanford, Calif (E.A.A., R.F., J.Y.K., B.B., J.M.S., A.J.C., T.Q.); HELIOS Heart Center Siegburg, Siegburg, Germany (U.G., S.O., E.G.); Agilent Laboratories, Palo Alto, Calif (A.V., A.K., A.T.); Foxhollow Technologies, Redwood City, Calif (X.H., A.S., J.B.S.); and Aviir Inc, Palo Alto, Calif (R.T.).